Webpage Copyright:Shandong Sihuan Pharmaceutical Co.,Ltd. 
ICP Register No.: 鲁ICP备17046678号-1 | Powered by www.300.cn JINAN

Shandong Sihuan Pharmaceutical Co.,Ltd. founded in 2004, is a technological enterprise engaged in the R & D, production and marketing of pharmaceutical raw materials.

 

The R & D center of our company is located in Overseas Student Pioneer Park in High-tech Zone in Jinan. There are comprehensive detection equipments, 60 sets of HPLC, 20sets of gas chromatograph, LCMS, ELSD, ultraviolet and visible spectrophotometer, freeze dryer and other advanced instruments. Our company owns a number of senior experts with international research background and level and has the comprehensive strength of lab study, pilot test and industrialization production. There are 6 doctors, over 98 masters and scientists and engineers more than 80%. The API production base of our company is located in Pingyuan Economic Development Zone in Shandong Province and covers an area of over 40mu. GMP pharmaceutical plant is located in Dezhou Development Zone in Shandong, covers an area of over 160mu and has high-standard modern workshop, administrative, laboratory and detection buildings, dormitory, mess and liver quarters, etc.

APIs
Intermediates
Anti-tumor
Anti-Diabetes Class
Anticardioascular disease
Arthritis meds
Antiviral class
Cephalosporins
2019 CPHI Exhibition in India

2019 CPHI Exhibition in India

Abstract:
2019 CPHI Exhibition in India
2019 CHPI Exhibition in Shanghai

2019 CHPI Exhibition in Shanghai

Abstract:
Exhibitions in 2018

Exhibitions in 2018

Abstract:
exhibitions in 2018
2018 Shanghai CPHI

2018 Shanghai CPHI

Abstract:
Wewillattend2018CPHIShanghai.TheboothNoisT1B26duringJun20-22.Welcometovisitus.
Nubeqa® (darolutamide) receives EU approval as a new treatment for men with non-metastatic castration-resistant prostate cancer

Nubeqa® (darolutamide) receives EU approval as a new treatment for men with non-metastatic castration-resistant prostate cancer

Abstract:
Copycats wanted: Pfizer, AZ and more under threat as China solicits generics

Copycats wanted: Pfizer, AZ and more under threat as China solicits generics

Abstract:
The U.S. FDA compiles a list of off-patent drugs without an approved generic to encourage the development of copycats. Now, the Chinese authorities are rolling out a similar initiative, only with some extra incentives.
China smacks 48 officials, including ex-FDA official, in Changsheng vaccine scandal

China smacks 48 officials, including ex-FDA official, in Changsheng vaccine scandal

Abstract:
China’s anticorruption authorities have punished 48 officials found responsible for the Changchun Changsheng Life Sciences vaccine scandal that provoked public outrage last summer.
EU expands look at Zhejiang Huahai as impurities show up in other 'sartans'

EU expands look at Zhejiang Huahai as impurities show up in other 'sartans'

Abstract:
A global recall may get expanded beyond valsartan as regulators continue to find potentially cancer-causing impurities in other “sartan” products. European regulators say they have found the same impurity discovered in valsartan in both losartan made by Hetero Labs and now irbesartan by Aurobindo Pharma.